These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 8927421)
1. Quantitative and qualitative AgNORs rates of prostate cancer on needle core biopsies: a multicentric study. Botticelli AR; Marandola P; Jallous H; Vicini D; Migaldi M; Speroni A; Mirando P Pathologica; 1995 Dec; 87(6):624-30. PubMed ID: 8927421 [TBL] [Abstract][Full Text] [Related]
2. Silver staining nucleolar organizer region in prostate cytology. Bittinger A; von Keitz A; Rüschoff J; Melekos MD Zentralbl Pathol; 1994 Mar; 140(1):103-6. PubMed ID: 7515666 [TBL] [Abstract][Full Text] [Related]
3. [AGNOR analyses of prostate carcinomas of high and malignancy]. Helpap B; Riede C Verh Dtsch Ges Pathol; 1993; 77():93-7. PubMed ID: 7511310 [TBL] [Abstract][Full Text] [Related]
4. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group]. Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478 [TBL] [Abstract][Full Text] [Related]
5. Nucleolar organizer regions in prostate cancer. Kobayashi S; Kuriyama M; Yamamoto N; Takahashi Y; Shinoda I; Takeuchi T; Deguchi T; Kawada Y Adv Exp Med Biol; 1992; 324():183-8. PubMed ID: 1283498 [TBL] [Abstract][Full Text] [Related]
6. Increasing the number of biopsies increases the concordance of Gleason scores of needle biopsies and prostatectomy specimens. Divrik RT; Eroglu A; Sahin A; Zorlu F; Ozen H Urol Oncol; 2007; 25(5):376-82. PubMed ID: 17826653 [TBL] [Abstract][Full Text] [Related]
7. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer. Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941 [TBL] [Abstract][Full Text] [Related]
8. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range. Haese A; Dworschack RT; Partin AW J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298 [TBL] [Abstract][Full Text] [Related]
12. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases. Aksoy Y; Oral A; Aksoy H; Demirel A; Akcay F Ann Clin Lab Sci; 2003; 33(3):320-3. PubMed ID: 12956448 [TBL] [Abstract][Full Text] [Related]
13. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging. Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354 [TBL] [Abstract][Full Text] [Related]
14. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL. Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081 [TBL] [Abstract][Full Text] [Related]
15. Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy? Abdel-Khalek M; Sheir KZ; El-Baz M; Ibrahiem el-H Scand J Urol Nephrol; 2005; 39(1):49-55. PubMed ID: 15764271 [TBL] [Abstract][Full Text] [Related]
16. CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator? Ang J; Lijovic M; Ashman LK; Kan K; Frauman AG Cancer Epidemiol Biomarkers Prev; 2004 Nov; 13(11 Pt 1):1717-21. PubMed ID: 15533898 [TBL] [Abstract][Full Text] [Related]
17. Nucleolar organizer regions as discriminators for the diagnosis of well-differentiated adenocarcinoma of the prostate. Schned AR Arch Pathol Lab Med; 1993 Oct; 117(10):1000-4. PubMed ID: 8215819 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma. Crook JM; Bahadur YA; Robertson SJ; Perry GA; Esche BA Cancer; 1997 Jan; 79(1):81-9. PubMed ID: 8988730 [TBL] [Abstract][Full Text] [Related]
19. The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate. Ornstein DK; Rao GS; Smith DS; Andriole GL J Urol; 1997 Mar; 157(3):880-3; discussion 883-4. PubMed ID: 9072591 [TBL] [Abstract][Full Text] [Related]
20. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions. Goel T; Garg S Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]